All stocks
AUROPHARMA
Large CapAurobindo Pharma · Pharma
₹1,690.5
+3.25% today
Market Cap
₹78,000 Cr
CMP
₹1,690.5
52W High
₹1,989.6
52W Low
₹1,226.9
P/E
21.8
P/B
2.6
ROCE
14.1%
Div Yield
1.13%
Peer comparison
6 companies · Pharma and nearest by size. Current company highlighted — click a header to sort.
| Company | CMP | MCap (Cr) | P/E | P/B | ROCE | ROE | D/E | Sales 3Y | Profit 3Y | OPM | Div Yld |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,945 | 4,45,000 | 38.2 | 6.4 | 18.9% | 16.8% | 0.04 | +16.6% | +22.4% | 24.1% | 0.76% |
| LUPIN | ₹2,363.5 | 92,000 | 34.2 | 5.1 | 18.2% | 16.4% | 0.12 | +16.8% | +19.3% | 23.8% | 0.85% |
| MUTHOOTFIN | ₹2,890 | 82,000 | 18.2 | 3.4 | 12.1% | 19.2% | 2.80 | +10.7% | +18.4% | 17.8% | 0.87% |
| SRF | ₹2,615 | 82,000 | 48.1 | 6.8 | 15.8% | 14.2% | 0.62 | +12.7% | +16.1% | 20.3% | 0.24% |
| AUROPHARMA | ₹1,658 | 78,000 | 21.8 | 2.6 | 14.1% | 12.8% | 0.18 | +14.2% | +11.4% | 18.4% | 1.13% |
| GRANULES | ₹873.85 | 14,000 | 28.2 | 3.8 | 16.8% | 14.1% | 0.32 | +16% | +18.5% | 21.2% | 1.53% |
Quarterly results
Last 8 quarters (₹ Cr unless noted)
| Quarter | Revenue | Op Profit | OPM | Other Inc | Interest | Dep | PBT | Tax | Net Profit | EPS | QoQ | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 FY25 | 3,026 | 590 | 19.5% | 22 | 24 | 88 | 499 | 124 | 375 | 7.97 | — | — |
| Q4 FY25 | 3,086 | 549 | 17.8% | 25 | 30 | 85 | 459 | 106 | 353 | 7.51 | -5.9% | — |
| Q1 FY26 | 3,269 | 625 | 19.1% | 56 | 19 | 112 | 551 | 142 | 409 | 8.69 | +15.9% | — |
| Q2 FY26 | 3,336 | 681 | 20.4% | 53 | 17 | 120 | 598 | 153 | 445 | 9.45 | +8.8% | — |
| Q3 FY26 | 3,420 | 671 | 19.6% | 63 | 29 | 123 | 583 | 140 | 443 | 9.42 | -0.4% | +18.1% |
| Q4 FY26 | 3,585 | 664 | 18.5% | 23 | 18 | 141 | 527 | 122 | 405 | 8.6 | -8.6% | +14.7% |
| Q1 FY27 | 3,741 | 766 | 20.5% | 28 | 32 | 142 | 620 | 147 | 473 | 10.06 | +16.8% | +15.6% |
| Q2 FY27 | 3,931 | 761 | 19.4% | 48 | 26 | 105 | 677 | 149 | 528 | 11.22 | +11.6% | +18.7% |
Profit & Loss — Annual
Last 4 years (₹ Cr)
| Year | Revenue | Op Profit | OPM | Net Profit | EPS | Tax Rate | Sales Growth | Profit Growth |
|---|---|---|---|---|---|---|---|---|
| FY23 | 10,433 | 2,023 | 19.4% | 1,395 | 29.65 | 25.3% | — | — |
| FY24 | 11,928 | 2,390 | 20% | 1,556 | 33.07 | 26.3% | +14.3% | +11.5% |
| FY25 | 13,689 | 2,669 | 19.5% | 1,791 | 38.07 | 23.3% | +14.8% | +15.1% |
| FY26 | 15,537 | 2,856 | 18.4% | 1,929 | 41 | 24.2% | +13.5% | +7.7% |
Balance sheet
Last 8 quarters (₹ Cr)
| Quarter | Share Capital | Reserves | Borrowings | Other Liab | Fixed Assets | CWIP | Investments | Other Assets | Total |
|---|---|---|---|---|---|---|---|---|---|
| Q3 FY25 | 1,500 | 25,982 | 5,548 | 8,277 | 16,036 | 1,252 | 9,067 | 14,953 | 41,307 |
| Q4 FY25 | 1,500 | 26,379 | 5,905 | 6,312 | 15,145 | 1,268 | 9,108 | 14,575 | 40,096 |
| Q1 FY26 | 1,500 | 27,300 | 5,608 | 6,135 | 14,977 | 1,380 | 8,130 | 16,057 | 40,543 |
| Q2 FY26 | 1,500 | 27,926 | 5,010 | 6,542 | 17,184 | 1,466 | 8,993 | 13,334 | 40,977 |
| Q3 FY26 | 1,500 | 28,694 | 5,311 | 7,756 | 15,769 | 1,657 | 8,821 | 17,014 | 43,261 |
| Q4 FY26 | 1,500 | 29,277 | 5,767 | 6,697 | 16,082 | 2,181 | 8,162 | 16,815 | 43,241 |
| Q1 FY27 | 1,500 | 30,084 | 5,400 | 7,031 | 16,200 | 2,255 | 10,505 | 15,055 | 44,015 |
| Q2 FY27 | 1,500 | 30,721 | 5,250 | 6,314 | 17,943 | 2,444 | 9,955 | 13,442 | 43,785 |
Cash flow
| Year | Operating | Investing | Financing | Net |
|---|---|---|---|---|
| FY23 | 1,751 | -1,492 | -607 | -348 |
| FY24 | 1,661 | -1,618 | -427 | -384 |
| FY25 | 2,222 | -1,889 | -629 | -296 |
| FY26 | 2,185 | -1,784 | -549 | -148 |
Shareholding pattern
PromoterGovtFIIDIIPublicOthers
Q3'25
Q4'25
Q1'26
Q2'26
Q3'26
Q4'26
Q1'27
Q2'27
Ratios
Last 4 years, with trend
| Ratio | FY23 | FY24 | FY25 | FY26 | Trend |
|---|---|---|---|---|---|
| Debtor Days | 57 | 67 | 29 | 65 | |
| Inventory Days | 22 | 40 | 76 | 30 | |
| Payable Days | 74 | 53 | 35 | 68 | |
| Cash Conversion Cycle | 5 | 54 | 70 | 27 | |
| Working Capital Days | 5 | 50 | 78 | 30 | |
| ROCE % | 11.4 | 12.4 | 13.1 | 13.7 | |
| ROE % | 10.6 | 11.9 | 12.3 | 12.8 | |
| OPM % | 19.4 | 20 | 19.5 | 18.4 |
Statement figures on this page are illustrative demo data until this company is scraped by the data pipeline. For educational purposes only. Not investment advice.